Vcanbio Cell & Gene Engineering Corp Current Liabilities
The Current Liabilities of Vcanbio Cell & Gene Engineering Corp (600645.SS) as of Sep 27, 2026 is 156.97 M CNY. In the previous year, Current Liabilities was 1.66 B CNY — a change of -90.56% (lower).
Get this data via API
Financial Data API
Current Liabilities
156.97 MCNY
YoY
-90.56%
Last updated:
The Vcanbio Cell & Gene Engineering Corp Current Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Current Liabilities | YoY |
|---|---|---|
| 156.97 MCNY | -90.56% | |
| 1.66 BCNY | +241.83% | |
| 486.33 MCNY | +4.09% | |
| 467.21 MCNY | +79.53% | |
| 260.24 MCNY | +21.92% | |
| 213.45 MCNY | -83.94% | |
| 1.33 BCNY | +2.97% | |
| 1.29 BCNY | +8.69% | |
| 1.19 BCNY | +0.51% | |
| 1.18 BCNY | +7.92% | |
| 1.09 BCNY | -8.95% | |
| 1.20 BCNY | +45.68% | |
| 825.38 MCNY | -13.77% | |
| 957.15 MCNY | +61.35% | |
| 593.20 MCNY | +17.34% | |
| 505.53 MCNY | +17.48% | |
| 430.30 MCNY | +8.62% | |
| 396.14 MCNY | +8.29% | |
| 365.80 MCNY | -6.98% | |
| 393.23 MCNY | +27.14% | |
| 309.29 MCNY | +10.37% | |
| 280.22 MCNY | +4.01% | |
| 269.41 MCNY | +29.22% | |
| 208.48 MCNY | -33.08% | |
| 311.52 MCNY | +29.30% | |
| 240.92 MCNY | -11.39% | |
| 271.89 MCNY | +3.52% | |
| 262.65 MCNY | -3.48% | |
| 272.12 MCNY | +53.90% | |
| 176.81 MCNY | -2.88% | |
| 182.05 MCNY | +85.46% | |
| 98.16 MCNY | +133.93% | |
| 41.96 MCNY | +75.00% | |
| 23.98 MCNY | — |
Vcanbio Cell & Gene Engineering Corp Stock analysis
Frequently Asked Questions about Vcanbio Cell & Gene Engineering Corp stock
Current Liabilities of Vcanbio Cell & Gene Engineering Corp is 156.97 M CNY in 2026.
Current Liabilities of Vcanbio Cell & Gene Engineering Corp changed from 1.66 B CNY to 156.97 M CNY, representing a -90.56% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Liabilities Vcanbio Cell & Gene Engineering Corp since 2006 – with annual values, charts, and detailed analysis.
Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.
Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Vcanbio Cell & Gene Engineering Corp historically and in real time.
Balance Sheet — Vcanbio Cell & Gene Engineering Corp
All Key Metrics — Vcanbio Cell & Gene Engineering Corp
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth